← k3vl4r
Log inGet started →

GENB (Generate Biomedicines Inc) Price Forecast

AI-generated price forecast for Generate Biomedicines Inc (GENB) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of October 2026: K3vl4r's calibrated AI forecast currently reads GENB as 1/1 bullish across its horizons (1 of 1 timeframes pointing up), with a last price of 12.22. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

12.22

AI outlook

1/1 bullish

Timeframes up

1 / 1

Share𝕏PostTelegram

GENB forecast by horizon

HorizonDirectionCalibrated move (end of horizon)
1-hour——
4-hour——
Daily~6 weeks out▲ Up+25.38%
Weekly——

Calibrated: each horizon's forecast is weighted by how often the model has called GENB's direction correctly over the last 30 days, and reversed where it has been wrong more often than right. A horizon votes only once it has enough resolved forecasts.

Latest GENB news

From the market-news feed the forecasts are read against.

  • Generate Biomedicines to Participate in November Investor Conferences · Yahoo · Oct 22
  • Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate · Yahoo · Oct 14
  • Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market · Yahoo · Oct 14
  • Generate Biomedicines: Zealand Deal For Obesity Programs May Not Be Quite What It Seems · SeekingAlpha · Oct 14
  • Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases · Yahoo · Oct 13

🔒

See the full GENB forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

GENB forecast — frequently asked

Will GENB go up?

K3vl4r's calibrated AI forecast currently reads GENB as 1/1 bullish — 1 of 1 forecast horizons point up, so the overall read is leaning to the upside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the GENB price prediction for 2026?

K3vl4r's model projects GENB toward $15.56 over the next ~6 weeks, a +25.4% move from $12.41. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

SHCCYHNBPTARAJBIOLGVNMYOHRTXTWSTCOCPERNABGMSKODMDXH

Will GENB reach…?

Will GENB reach $20.00?Will GENB reach $25.00?Will GENB reach $50.00?

Or see the full GENB price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare GENB

GENB vs SHCGENB vs CYHGENB vs NBPGENB vs TARAGENB vs JBIOGENB vs LGVN

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rTop PicksTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.